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Abstract 
There is increasing appreciation of the role that vaginal microbiota play in health and 
disease throughout a woman’s lifespan. This has been driven partly by molecular 
techniques that enable detailed identification and characterisation of microbial 
community structures. However, these methods do not enable assessment of the 
biochemical and immunological interactions between host and vaginal microbiota 
involved in pathophysiology. This review examines our current knowledge of the 
relationships that exist between vaginal microbiota and the host at the level of the 
vaginal mucosal interface. We also consider methodological approaches to 
microbiomic, immunologic and metabolic profiling that permit assessment of these 
interactions. Integration of information derived from these platforms brings the 
potential for biomarker discovery, disease risk stratification and improved 
understanding of the mechanisms regulating vaginal microbial community dynamics 
in health and disease. 
 
 
 
Highlights  Vaginal microbiota-host interactions play a critical role in the dynamics of 
health and disease states during a woman’s lifetime  Lactobacillus species dominance of the vagina broadly indicates health, 
whereas Lactobacillus species depletion and increased diversity is more often 
associated with pathologies (e.g. bacterial vaginosis, poor pregnancy 
outcomes, sexual transmitted infections) 
 Sampling of the vaginal mucosa and analysis by next-generation sequencing 
combined with immunological and metabolic profiling techniques can be used 
for detailed characterised of patient-level microbial composition and host 
response 
 Optimisation of the methodological and analytical workflows for these multi-
omic platforms is important for limiting technical and experimental biases that 
can hinder interpretation and reproducibility of data 
  Ambient ionisation MS techniques such as DESI-MS permit rapid, direct 
analysis of vaginal swabs and the detection of metabolite changes associated 
with vaginal microbiota composition 
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1. Vaginal microbiota in health and disease  
The human vagina hosts a complex microbial ecosystem that has long been 
recognised to influence health outcomes throughout a woman’s lifetime [1]. As early 
as the late 19th century, bacteria and viruses present in the vagina began to be 
causally linked to lower reproductive tract diseases such as gonorrhoea and genital 
herpes [2]. Around the same time, Doderlein discovered a bacilli (later attributed to 
Lactobacillus acidophilus [3]) in vaginal secretions of pregnant women, which was 
described as having antagonistic effects towards pathogens [4]. It was also noted 
that vaginal secretions deplete of bacillus were often colonised instead by high 
numbers of morphologically distinct microorganisms with an elevated pH [5]. These 
clinical features today would be attributed to symptomatic bacterial vaginosis (BV) 
[6]. A century later, the concept of the relationship between reproductive health and 
lactobacillus dominance remains, yet through the application of modern culture-
independent and molecular-based methods, is being redefined with increased 
appreciation of the complexity and dynamics of community structure within the 
vagina [7, 8]. 
 
1.1 The “healthy” and “unhealthy” vaginal microbiome 
 
The vaginal microbiome describes the microorganisms (bacteria, fungi and viruses), 
their genomes and their surrounding biochemical environment in its entirety [9]. 
Establishment of the vaginal microbiome begins at the time of birth with delivery 
considered a key seeding event [10, 11]. In the immediate postpartum period, the 
residual effects of maternal oestrogen on the female neonate promotes thickening 
of the vaginal epithelium and deposition of glycogen, which is used as a primary 
carbon source by lactic acid-producing bacteria [12]. As estrogen levels fall these 
effects dissipate by around the fourth week of life when the vaginal epithelium 
becomes less stratified, glycogen content is reduced and vaginal pH increases [13]. 
This is accompanied by a shift toward a high-diversity community structure that 
persists throughout childhood [14] until just prior to the onset of menarche when it 
begins to resemble that of reproductive-aged women [15]. Cross-sectional studies of 
asymptomatic women have shown that vaginal microbiota profiles can be classified 
into at least five main groups often referred to as community state types (CST) [16]. 
Four of these groups are characterised by almost complete dominance of either 
Lactobacillus crispatus (CST I), Lactobacillus gasseri (CST II), Lactobacillus iners 
(CST III) or Lactobacillus jensenii (CST V), whereas CST IV is characterised by a 
low abundance of Lactobacillus species and increased diversity and richness of 
anaerobic bacteria often associated with BV. However, longitudinal studies reveal 
the dynamic nature of these vaginal microbial community compositions, which in 
some women flux and alter with hormonal changes during menstruation, while in 
other women it remains stable over long periods of time [17]. During pregnancy, 
where circulating concentration of oestrogen progressively rise [18], there is a 
reduction in vaginal bacterial diversity and a further shift towards Lactobacillus spp. 
dominance [19, 20]. Following delivery, when maternal oestrogen levels fall, vaginal 
Lactobacillus spp. dominance decreases and there is a shift towards a high-diversity 
microbiota community structure [19] that can persist in some women for up to one 
year postpartum [21, 22]. At menopause, reduced oestrogen levels are associated 
with decreased vaginal epithelial glycogen deposition, depletion of Lactobacillus spp. 
and increased colonisation of high-diversity microbial communities [23]. 
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While Lactobacillus species dominance of the lower genital tract is generally 
associated with states of health, a shift in microbial composition towards a high-
diversity structure is often associated with disease risk and pathologies such as 
urogenital tract infections [24] and BV [25]. High diversity community structures and 
low relative abundance of Lactobacillus species are also associated with increased 
risk of sexually transmitted diseases such as human immunodeficiency virus (HIV) 
[26, 27], human papillomavirus infection and the progression of cervical 
intraepithelial neoplasia towards cervical cancer [28, 29]. Adverse pregnancy 
outcomes such as miscarriage and preterm birth have also been linked with vaginal 
pathogen infection or abnormal vaginal microbial composition [21, 30-34]. Although 
less studied, the fungal component of the microbiome, termed the “mycobiota”, may 
also be an important mediator of health and disease [35]. Many yeast species are 
vaginal commensals, however overgrowth of some species such as Candida 
albicans occurs commonly in the population with at least 75% of women 
experiencing symptomatic vaginal candidiasis at least once in their lifetime [36]. 
Common Candida species can cause urinary tract infections [37] and HIV viral load 
in vaginal fluid of HIV-positive women is significantly increased in the presence of 
Candida colonisation [38]. The precise mechanisms by which fungi act as 
modulators of microbiome structure in the context of health and disease states are 
poorly defined and warrant further investigation. 
 
Lactobacillus species domination of the vaginal microbiome has often been 
described as a hallmark of vaginal health, however a number of recent studies have 
shown that this is not always the case. High diversity compositions deplete of 
Lactobacillus species are prevalent in around 40% of reproductive-aged women of 
Black and Hispanic ethnic background in contrast to around 10-20% of women from 
White or Asian ethnic backgrounds [39, 40]. It is also noteworthy that vaginal 
microbiota or community compositions associated with pathology or disease states 
can often still be observed in asymptomatic, healthy controls. This highlights the 
likelihood of individual-level microbiota:host interactions, mediated by factors such as 
genetic background and individual host immunity, as being key determinants of 
either normal or pathological responses to vaginal microbiota [1]. Methodologies that 
permit assessment of these interactions can broadly be divided into techniques that 
facilitate detection and identification of microbiota, and those that permit examination 
of the functional response of both microbiota and host.  
 
2. Identification and characterisation of vaginal microbiota 
 
In a clinical setting, analysis of vaginal microbes is performed almost exclusively 
using a combination of culture and microscopy based methods. This typically 
involves the analysis of material collected from vaginal swabs by routine aerobic, 
anaerobic and fungal culture using selective media combined with assessment of 
microscopic features of the samples (e.g. the presence or absence of clue cells and 
bacterial morphotypes) [41-44]. However, these methods are limited as many 
microbes cannot be cultured in vitro and information regarding relative abundance of 
specific species within a community cannot be obtained. As a result, culture-
independent, molecular-based approaches are increasingly applied to assess 
vaginal microbiota composition and structure and will be primarily described in this 
review [45].  
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2.1 Sampling and isolation of microbial genetic material 
 
Sampling of vaginal microbiota is most commonly performed using a rayon or cotton 
swab, however cytobrushes are also used where exfoliation of the top layer of 
epithelial cells is required (e.g. for cytological detection of dysplasia in vaginal 
intraepithelial neoplasia). Although vaginal microbiota composition and diversity 
measurements appear to be comparable between the main sampling devices [46, 
47], DNA and protein yields can differ [47, 48] and this should be taken into account 
during study design.  
 
Isolation and extraction of genomic DNA from vaginal microbiota requires cell lysis, 
which is generally performed using enzymatic, chemical and/or mechanical (bead 
beating) methods followed by the phenol-chloroform-isoamyl alcohol DNA 
precipitation or using more popular silica based columns. DNA extraction is a major 
source of bias in 16S rRNA gene sequencing analyses [49-51]. Several DNA 
extraction methods from vaginal swabs have been described yet there is no one 
approach regarded as the gold standard [19, 32, 52-59]. An enzyme cocktail 
consisting of mutanolysin and lysostaphin, in addition to lysozyme, is commonly 
used in order to lyse those bacterial species resistant to lysozyme digestion [60, 61]. 
For example, vaginal bacterial species such as Neisseria gonorrhoeae, Proteus 
mirabilis and Staphylococcus aureus are resistant to c-type lysozyme due to the 
modified peptidoglycan structure of their O-acetylated peptidoglycans [62]. Instead 
these bacteria are sensitive to mutanolysin, a N-acetylmuramidase that catalyses the 
cleavage of ȕ-N-acetylmuramyl-(1 ĺ 4)-N- acetylglucosamine linkage of the Gram-
positive bacterial cell wall. Other bacteria commonly found in the human vagina such 
as Streptococcus and Lactobacillus species are also sensitive to mutanolysin [52, 
63]. Although the use of mechanical disruption by bead beating following enzymatic 
lysis is widely used to increase DNA yields [64-66] and has been shown to improve 
overall representation of microbial diversity [61], excessive bead beating can lead to 
shearing of DNA and increased formation of chimeric products during polymerase 
chain reaction (PCR) amplification [67] therefore it is important to optimise speed 
and duration of mechanical disruption [68]. 
 
Extracted microbial DNA is then amplified by the PCR and analysed using whole 
genome-shotgun sequencing or targeted sequencing of bacterial gene amplicons 
derived from specific genomic regions (e.g. 16S rRNA and 18S rRNA genes) [24]. 
Resulting sequence data are then aligned and assigned using highly curated, broad 
coverage 16S rRNA sequence libraries [69] or more targeted reference databases 
enriched for taxa commonly isolated from the vagina [70]. Downstream of DNA 
extraction, various studies have highlighted additional sources of potential bias that 
can lead to erroneous findings and limit comparison of data across studies of vaginal 
microbiota. These include, but are not limited to, primer design and PCR 
amplification efficiency [71-73], sequencing depth [74] and data processing [75]. 
Selection of primers is particularly important when considering characterisation of 
vaginal microbiota communities by 16S rRNA gene sequencing. Bacterial 16S rRNA 
genes contain nine “hypervariable regions” (↑1 – V9) that demonstrate considerable 
sequence diversity among different bacteria, thus permitting their use for species 
identification [76]. However, as current high-throughput sequencing platforms are 
limited to the analysis of short, partials sequence amplicons, this sequence diversity 
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also means that no single hypervariable region can differentiate among all bacteria 
species [77, 78]. Uneven amplification of certain species can thus lead to either an 
under- or over-representation of specific species within a microbial community [79-
81]. For example, the V1-V3 region of the 16S rRNA gene is often targeted for 
vaginal microbiota characterisation as it permits the most robust classification of the 
most common vaginal Lactobacillus species (L. crispatus, L. iners, L. gasseri, and L. 
jensenii)[82]. However, the commonly used universal forward (27F) primer has 
mismatches against the G. vaginalis 16S rRNA gene sequence, a key bacterium 
associated with high diversity communities [77, 83], potentially leading to lower 
representation of these sequences within samples [77, 84]. This can be overcome 
through the use of a mixed formulation of the 27F forward primer (27F-YM), which 
permits maintenance of the rRNA gene ratio of Lactobacillus spp. to Gardnerella 
spp. [77]. Primers targeting the V6 region have also been used to characterised 
vaginal microbiota however this region has known bias against Sneathia, 
Leptotrichia, Ureaplasma and Mycoplasma species [85]. Mixture experiments using 
mock communities composed of known quantities of bacterial isolates or PCR 
products have been proposed recently as an effective approach for identifying and 
quantifying such biases [49]. 
 
3. Functional assessment of vaginal microbiota:host interactions 
 
Molecular-based, culture independent approaches for identifying and characterising 
vaginal microbiota have revolutionised our understanding of community composition. 
However, these approaches fail to capture the functional interactions occurring 
between microbiota and the host that ultimately dictate health and disease 
phenotypes in the reproductive tract. Microbial composition of the vagina can be 
rapidly altered through host behaviour (e.g. sexual activity, douching, antibiotics) but 
it is also shaped by intrinsic selection pressures including nutrient availability, the 
ability to adhere and attach to host epithelial surfaces or other microbiota, chemical 
composition of the local environment and the host innate and adaptive immune 
responses [8]. Assessment of the biochemical and immunological interplay between 
host and vaginal microbiota are therefore critical for understanding their functional 
implications in health and disease. As described below, this is increasingly being 
achieved through the integration of microbiomic, metabolomic and immunologic 
analyses of vaginal mucosa samples. Although beyond the scope of this review, 
readers are encouraged to examine strategies and approaches for integrating and 
fusing these forms of multi-omic datasets [86-88]. 
 
3.1 Vaginal microbiota and local immune response 
As reviewed elsewhere [89], innate and adaptive mucosal immune responses in the 
vagina protect against colonisation by pathogens. This involves coordinated immune 
cell trafficking and activation regulated by endocrine signalling [90], tightly mediated 
expression of pattern recognition receptors (PRR) throughout the reproductive tract 
[91, 92] and secretion of antimicrobial peptides like beta-defensins, elafin and 
secretory leukocyte protease inhibitor (SLPI) [93-95]. Although the immune system 
appears to be largely tolerant of Lactobacillus colonisation, certain species can 
dampen or enhance local immune and inflammatory responses. For example, 
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Lactobacillus crispatus dominated vaginal communities are associated with lower 
levels of pro-inflammatory cytokines (e.g. IL-1α, IL-1ȕ, and IL-8) compared to 
communities dominated by BV-associated bacteria or Lactobacillus iners [96-101]. 
Furthermore, BV is also linked to decreased levels of the anti-inflammatory, 
antimicrobial peptide SLPI [102, 103]. A detailed description of inflammatory and 
immune mediators associated with differing vaginal microbial communities and 
pathologies is provided in Table 1. 
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Table 1. Examples of cytokine responses at the vaginal mucosal interface in response 
to altered microbiota composition in pathology and infection.  
Study cohort Cytokines/Chemokines References 
BV IL-1α Ĺ [96],[99]  
 
IL-1ȕ Ĺ [96],[104],[105],[97],[106],[107]  
 
TNF-α Ĺ [96] 
 
IFN-Ȗ Ĺ [96] 
 
IL-10 Ĺ [96] 
 
IL-8 Ĺ [96],[108],[107]  
 
IL-1βp70 Ĺ [96],[106] 
 
IL-4 Ĺ, IL-4 Ļ [96], [109] 
 
FLT-γL Ĺ [96] 
 
Eotaxin Ļ [104] 
 
IL-β Ĺ [110] 
 
IL-1βp70 Ĺ [110] 
 
IL-6 Ĺ [110],[111],[107],[108]  
 
G-CSF Ĺ [111] 
 
IP-10 Ļ [106] 
 
Elafin Ļ [112] 
 
Mip-1ȕ Ĺ [111] 
 
RANTES Ĺ [111] 
 
Gro-α Ĺ [111] 
 
hBDβ Ĺ [109] 
 
hD5 Ĺ [109] 
 
TGF-ȕ1 Ļ [107] 
 
ȕ-defensin 4 Ĺ [108] 
 
Endotoxin Ĺ [99] 
HPV IL-β Ĺ, IL-1β Ĺ, IFN-Ȗ Ĺ [110] 
  
 
  
 
Cervicitis/Vaginitis IL-1ȕ Ĺ, TNF-α Ĺ, IL-6 Ĺ [105] 
 Neutral sphingomelinase Ļ  
 
BV = Bacterial vaginosis; IFN = Interferon; FLT-3L = Fms-related tyrosine kinase 3 ligand; G-CSF = Granulocyte-
colony stimulating factor; Gro = growth regulated oncogene; hBD = human beta defensin; hD = human defensin; 
IL = Interleukin; IP = interferon gamma-induced protein; Mip = Macrophage inflammatory protein; Normal T Cell 
Expressed and Secreted; RANTES = Regulated on activation; TGF = Transforming growth factor; TNF = Tumour 
necrosis factor;  
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In vitro studies using epithelial cell models have shown that immune and 
inflammatory responses from vaginal epithelial cells are species specific. Co-culture 
of Gardnerella vaginalis and Atopobium vaginae with vaginal epithelial cells leads to 
the upregulation of pro-inflammatory cytokines (e.g. IL-6, IL-1ȕ, TNFα and IL-8) and 
chemokines (e.g. RANTES, MIP-1ȕ) as well as antimicrobial peptides (e.g. hBD-2) 
[108, 111, 113, 114]. In contrast, other species often detected in BV cases such as 
Prevotella bivia do not elicit similar pro-inflammatory responses indicating differing 
pathogenicity of some BV-associated bacteria [114]. A summary of key in vitro 
inflammatory (cytokine and chemokine) responses by vaginal epithelial cells in co-
culture with commensal or pathogenic vaginal microbes is provided in Table 2. 
 
Table 2. Summary of inflammatory response by vaginal epithelial cells 
following co-culture with commensal or pathogenic microbes.  
Co-Culture Upregulated Cytokines/Chemokines (unless indicated 
otherwise) References 
Atopobium 
vaginae 
Membrane associated mucin, CCL20, hBD-2, IL-1ȕ, IL-6, 
IL-8, TNF-α, hBD-3, G-CSF, IP-10, Mip Iȕ, RANTES, Gro-
α 
[114], [111] 
 
 
Candida 
albicans TNF-α, Il-8, CXCL8, hBD2, IL-1α [115], [116] 
Gardnerella 
vaginalis IL-6, IL-8, G-CSF, IP-10, Mip-Iȕ, RANTES, Gro-α, IL-1ȕ [111] 
Lactobacillus 
crispatus AMPĻ, defensins Ļ  [114], [113] 
Lactobacillus 
iners IL-6 ļ, Il-8 ļ, PRR Ĺ, SLPIĹ [114] 
Lactobacillus 
vaginalis 
hBD2, IL-6, IL-8 
 
[111] 
Mobiluncus 
curtisii IL-6, IL-8, G-CSF, IP-10, Mip-1ȕ, RANTES, Gro-α, hBDβ [111] 
Neisseria 
gonorrhoeae IL-8, IL-6, CD-54, CD-66  [117] 
Prevotella bivia IL-6, IL-8, G-CSF, IP-10, Mip-Iȕ, RANTES, Gro-α, hBDβ, IL-1ȕ 
[111] 
 
Streptococcus 
epidermidis IL-1ȕ, 1L-1RA, 1L-8, GCSF, TNF-α [113] 
 
CXCL = C-X-C motif ligand; G-CSF = Granulocyte-colony stimulating factor; Gro = growth regulated 
oncogene; hBD = human beta defensin; IP = interferon gamma-induced protein; IL = Interleukin; MDC 
= Macrophage-derived chemokine; Mip = Macrophage inflammatory protein; PRR = Pattern 
recognition receptor; RANTES = Regulated on activation; SLPI = secretory leukocyte peptidase 
inhibitor; TNF = Tumour necrosis factor. 
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3. Microbial and host metabolism in the vagina 
3.1 Sugar compound metabolism 
Mucus produced by the cervix contains a rich mixture of carbohydrates, fatty acids, 
and trace elements [118], which in combination with glycogen depositions found in 
the vaginal epithelia [119, 120], provides the majority of nutrients utilised by vaginal 
microbiota. Lactobacillus spp. have the capacity to hydrolyse glycogen into 
maltodextrins, maltobiose and maltose in vaginal fluid by host-encoded α-amylase 
[121, 122]. Consistent with this, women clinically diagnosed with BV have lower 
vaginal levels of α-amylase [121]. Breakdown products of glycogen are used as 
primary carbon sources by Lactobacillus species during anaerobic glycolysis, which 
results in the production of lactic acid [123, 124] and contributes to their capacity to 
dominate the niche. Metabolic profiling of vaginal mucosa comparing women with BV 
and healthy controls, revealed that relative concentrations of maltodextrins, 
maltotriose, maltopentose and maltose are positively correlated to relative 
abundances of Lactobacillus crispatus and Lactobacillus jensenii whereas levels of 
maltotriose, maltotetraose, maltopentaose and maltohexaose are decreased in BV 
cases [125]. In addition, BV is also characterised by comparatively low levels of 
simple sugars and sugar alcohols such as lactate, fructose and mannitol as well as 
metabolites involved in glycerol metabolism, namely glycerol and glycerol-3-
phosphate. Further, it has been reported that N-acetylneuraminate, ethanolamine, 
and the lipid metabolites 4-trimethylaminobutanoate/gamma-butyrobetaine and 3-
methyl-2-oxobutanoate are associated with colonisation by BV associated 
Eggerthella spp. and Megasphaera spp. [126]. 
Major functional metabolic differences also exist between closely related bacterial 
species. For example, a recent study comparing the genomes of the two most 
common inhabitants of the vagina, Lactobacillus crispatus and Lactobacillus iners, 
revealed the former has a genome size almost double that of the latter (4300 versus 
2300 genes, respectively) [127]. A consequence of this is a reduced capacity for 
Lactobacillus iners to ferment as many carbon sources as Lactobacillus crispatus. 
Although both species have the capacity to metabolise glucose, mannose, maltose, 
and trehalose, only Lactobacillus crispatus has the genetic potential to ferment 
lactose, galactose, sucrose and fructose. Interestingly, Macklaim et al., reported that 
in BV cases Lactobacillus iners has the genetic and metabolic capacity to uptake 
and utilise glycerol as a carbon source for glycolysis or glycerophosholipid 
metabolism [128], which may provide a possible explanation for it’s ability to co-
colonise with BV-like community compositions. 
As mentioned previously, the end product of anaerobic glycolysis in Lactobacillus 
spp. is lactic acid, which is widely considered a hallmark of the species and therefore 
a proxy for good vaginal health. Under anaerobic growth conditions, physiological 
concentrations of lactic acid (55-111 mM) inactivate various BV associated bacteria 
[129] and viruses [130]. However, other bacteria often associated with BV also have 
the capacity to produce lactic acid including species of Atopobium, Streptococcus, 
Staphylococcus, Megasphaera and Leptotrichia, which are capable of both 
homolactic or heterolactic acid fermentation [131]. Vaginal epithelial cells produce 
almost uniquely the L-lactic acid enoantiomer, whereas major Lactobacillus spp. can 
encode genes for the production of both L- and D- enantiomers [132]. This appears 
to be of functional importance as women exhibiting vaginal microbiota dominated by 
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Lactobacillus iners have an increased ratio of L to D-lactic acid compared to women 
with Lactobacillus crispatus dominance, which is associated with increased 
expression of vaginal extracellular matrix metalloproteinase inducer (EMMPRIN) and 
activation of matrix metalloproteinase-8 (MMP8), an enzyme involved in remodelling 
of the fetal membranes and the cervix prior to the onset of labour [80].  
3.2 Short chain fatty acids (SCFAs) 
In contrast to lactic acid, SCFAs associated with high diversity vaginal microbial 
compositions have markedly less antimicrobial activity and appear to potentiate a 
pro-inflammatory vaginal environment [133-136] that may ultimately lead to reduced 
barrier integrity of the vaginal epithelium and increased risk of infection [137]. 
Elevated levels of SCFAs are readily detectable in vaginal mucosa collected from BV 
patients and include acetate, propionate, butyrate, succinate, formate, valerate and 
caproate [138-145]. Many BV associated bacteria are known SCFAs producers 
including Bacteroides (succinate) Peptococcus (butyrate and acetate), Clostridium 
and Dialister (propionate) species [139, 144, 146, 147]. Gardnerella vaginalis has 
also been shown to produce acetate and succinate [148]. Despite being historically 
associated with BV, it has recently been shown that succinate is also elevated in 
microbial communities dominated by Lactobacillus crispatus [149, 150]. Correlation 
analyses of matched vaginal metabolomic and microbiomic profiles has recently 
identified Gardnerella vaginalis as a major producer of Ȗ-hydroxybutyrate (GHB) in 
vaginal secretions [149], however the role of GHB in the pathology of BV remains to 
be determined. 
 
3.3 Lipid metabolism 
Significant alterations in lipid metabolism can be observed in BV and appears to 
mainly involve eicosanoid and carnitine synthesis pathways. For example, BV has 
been associated with higher levels of the signalling eicosanoids, 12-HETE, a 
biomarker for inflammation, and lower levels of its precursor, arachidonate 
suggesting conversion of arachidonate to 12-HETE by BV-associated bacteria [125]. 
In contrast, carnitine, a product of lysine or methionine degradation involved in 
transport of long-chain fatty acids, is lower in vaginal mucosal samples isolated from 
BV patients while levels of the precursor, deoxycarnitine and ascorbic acid are 
higher [125]. Acyl-carnitines such as acetylcarnitine, propionylcarnitine, and 
butyrylcarnitine have also been previously reported to be lower in BV [22]. One 
proposed mechanism for lower carnitine levels in BV is through their conversion to 
trimethlyamine by BV associated bacteria [125].  
 
3.4 Bioamines   
Host cells are capable of producing putrescine, spermine and spermidine, which play 
important roles in immune regulation, lipid metabolism, nucleic acid stabilisation and 
cell division, however, certain bioamines are exclusively of microbial origin [151]. 
Most bioamines, with the exception of spermine and spermidine, are produced via 
specific amino acid decarboxylation reactions and modify redox status through 
consumption of hydrogen ions and the subsequent reduction of intracellular and 
extracellular acidity [152, 153]. Metabolic profiling studies of the Lactobacillus spp. 
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deplete, high-diversity communities as seen in BV have identified elevated levels of 
several bioamines including cadaverine, putrescine, agmatine and tyramine, which 
contribute to malodour [125, 154, 155].  
 
3.5 Amino acids 
Vaginal mucosa isolated from patients with BV contains numerous amino acid 
catabolites, whereas Lactobacillus crispatus and Lactobacillus jensenii dominance of 
the vaginal microbiota are associated with the presence of intact amino acids and 
dipeptides suggesting increased utilisation of amino acids in BV as a carbon and 
nitrogen source [125]. The amino acid arginine typically can act as a precursor for 
polyamines putrescine, spermidine and spermine and consistent with this, BV is 
associated with reduced arginine and increased putrescine [125]. Other amino acids 
depleted in vaginal secretions in BV include leucine, isoleucine, alanine, valine 
tyrosine and tryptophan [156].  
 
4. Metabolic profiling approaches for characterisation of host-microbiota 
interactions 
 
4.1 Sampling and metabolite extraction 
 
Vaginal swab sampling [19, 33, 34, 149, 157, 158] or the collection of cervicovaginal 
lavage (CVL) [125, 156, 159] represent the two most common sampling techniques 
for metabolic profiling studies of the vaginal mucosa. To ensure adequate amount of 
vaginal mucosa is collected, the swab is rolled in a clockwise direction and moved 
across all four quadrants of the posterior fornix. The wet weight of the sample should 
be recorded to permit normalisation of metabolite concentrations and facilitate 
sample-to-sample comparison of data. For metabolic profiling studies it is 
recommended that swabs be stored directly in a sterile 1.5 ml microfuge tube without 
storage media to avoid contamination and matrix suppression when using MS based 
techniques. Collected swabs should be immediately processed or stored at -80°C. 
A schematic workflow for metabolic profiling assays from vaginal swab extractions 
and assessment of microbial composition and host immune response is presented in 
Figure 1. There exists a vast array of extraction procedures that can be used for 
isolating a broad range of metabolites from vaginal swabs. Ideally the method should 
permit robust and reproducible capture of metabolites with different chemical 
properties (e.g. polarity, solubility) and across a wide concentration range. Most 
commonly, a biphasic, liquid-liquid extraction is performed directly on swab tips but 
care should be taken to optimise the volumes, ratios and pH of organic and aqueous 
solvents used for the procedure. It is also worth noting that particular solvents can 
degrade swab material and generate contaminants that overlap with genuine 
metabolite signals. In the example presented in Figure 1, a 1:1 methanol:water 
mixture is added to a swab in a centrifuge tube to reach a suggested final 
concentration of 50 mg vaginal fluid/ml. The swab is then vortexed and sonicated to 
enhance release of metabolites from the swab. For entire recovery of extracted 
material, the swab can be inverted and transferred to a new microfuge tube, before 
being centrifuged with 8000 x g for 2 min. The swab tip is then removed using sterile 
forceps and the supernatants pooled before centrifugation at 16 000 x g for 10 min to 
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remove insoluble material. The metabolite extracts can then be further cleaned up 
and pre-concentrated with the use of solid phase microextraction cartridges. Extracts 
are then evaporated using a SpeedVac with the heating function turned off to avoid 
metabolite degradation. 
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Figure 1. Example workflow for multi-omic microbiomic, immunologic and metabolome studies 
of the vaginal mucosal interface. Step wise workflow and time scheme illustrated for vaginal 
mucosal sampling, sample preparation and analysis for next generation sequencing, multiplexed 
immunoassay and metabolite profiling assays using NMR, GC-MS and/or LC-MS.  
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4.2 Comparison of different platforms for metabolomic assays 
No single analytical instrument or instrumental method can detect all metabolites 
present in a given metabolome, thus numerous platforms are often used for 
metabolomic profiling including nuclear magnetic resonance (NMR) spectroscopy, 
Fourier transformed-infrared spectroscopy (FT-IR), and mass spectrometry (MS) 
coupled to separation techniques including gas chromatography-MS (GC-MS), or 
liquid chromatography-MS (LC-MS) or with direct flow injection methods [160-164]. 
NMR offers high throughput, high reproducibility metabolic profiling, minimal sample 
preparation and is a non-discriminatory and non-destructive technique. Unlike mass 
spectrometry, it is inherently quantitative thus permitting absolute concentration of 
detected metabolites. However, only medium to high abundance (μM) metabolites 
can be detected with NMR and the identification of individual metabolites based on 
chemical shift signals that cause sample clustering in multivariate analysis is 
challenging in complex mixtures [165].  
Mass spectrometry (MS) offers high sensitivity detection of a wide variety of 
compounds including fragmentation patterns which contribute to the identification of 
the metabolites [165]. Both targeted profiling (in which metabolites are known a 
priori) and fingerprinting can be carried out using MS-based metabolomics 
approaches. Further, the use of separation techniques prior to MS reduces the 
complexity of the mass spectra due to metabolite separation in a time dimension, 
provides isobar separation, and delivers additional information on the 
physicochemical properties of the metabolites. However, such methods generally 
require a sample preparation step, which can cause metabolite losses, and based on 
the sample introduction system and the ionisation technique used, specific 
metabolite classes may be biased. Therefore, parallel application of several 
techniques, for example, GC-MS and LC-MS is desirable for comprehensive analysis 
of the metabolome [166-169]. This results in increasing time demand for analysis 
[170]. 
4.3 Direct infusion and ambient ionization techniques for rapid and direct sample 
analysis 
Direct infusion measurements are most effective in combination with high-resolution 
mass spectrometers. This allows the determination of thousands of compounds 
based on their accurate masses in a single experiment. However, the simultaneous 
detection of so many compounds can in turn lead to sensitivity loss due to ion 
suppression effects. Ambient ionisation techniques are particularly advantageous 
compared to direct infusion methods as samples can be directly analysed in their 
native state [171, 172]. For routine clinical applications, faster and simpler 
methodologies are desirable for enabling the analysis of biomolecules in real time 
and without sample preparation to ensure effective, reproducible and immediate 
results. A promising technique for direct, on-sample analysis is desorption 
electrospray ionisation (DESI) MS [112]. DESI is an atmospheric pressure 
desorption ionisation method developed for the direct and rapid analysis of samples 
on arbitrary solid phase samples [173, 174]. Sampling and ionisation for DESI can 
be performed directly on various solid/gas interfaces for the ionisation of a variety of 
compounds ranging from lipids, peptides, proteins, drug molecules and their 
metabolites to secondary metabolites such as organic acids or amino acids. 
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Recently, we developed an analytical approach for the direct analysis of standard 
medical rayon swabs for rapid (<3 minutes) mucosal diagnostic point of care 
applications using DESI-MS [175]. In this study, we showed that DESI-MS applied to 
vaginal swabs permitted the detection of metabolite changes associated with BV 
including altered levels of lactate, short chain fatty acids and bioamines. Further it 
was demonstrated that DESI-MS offers the potential for culture-free microbial 
identification by permitting the rapid detection of microbiota-specific and associated 
metabolites. 
4.4 Mass analysers used for targeted and untargeted metabolomics 
Single quadrupol (Q), triple quadrupol (QqQ), quadrupol ion trap (QIT) and Orbitrap 
and Time of Flight (TOF) are the most frequently used mass analysers [176-178]. 
Single quadrupole is the simplest mass analyser, and can operate in the selected ion 
monitoring (SIM) mode which is preferred for targeted metabolomics due to its 
significantly higher sensitivity [179]). Triple quadrupole (QqQ) instruments have the 
advantage over single quadrupole in being able to perform selected reaction 
monitoring (SRM) experiments [180]. In SRM a specific precursor ion is selected in 
the first quadrupole, followed by fragmentation in the second quadrupole acting as a 
collision cell and finally, specific fragment ions are monitored in the third quadrupol to 
increase both sensitivity and selectivity [181]. The Orbitrap is one of the most 
recently developed mass analysers, and provides high mass resolution (>100.000 
full-width at half maximum), high mass accuracy (2-5 ppm), high acquisition rates (12 
Hz) and a wide dynamic range [182]. 
While mass accuracy describes the precision of the measured m/z, the mass 
resolving power describes the ability of a mass spectrometer to provide a specified 
value of mass resolution, i.e. generate distinct signals for two ions with a small m/z 
difference [183]. Untargeted metabolomics allows exploratory analyses of the 
majority of metabolites contained in a biological sample. The main features for mass 
analysers used frequently in untargeted metabolomics are mass resolution power, 
mass range and mass accuracy, sensitivity and linear dynamic range. In order to 
distinguish between isomeric and isobaric analytes, as is often the case for 
untargeted metabolomics, high-resolution mass spectrometers are typically the 
instrument of choice. High resolution also allows the calculation of empirical 
formulas, which enables a better confidence for compound identification [183]. 
The choice of mass analyser depends on the characteristics of the untargeted 
profiling technique to be deployed. For DESI-MS and other techniques that generate 
mass spectra without another dimension for feature deconvolution, mass resolution 
and mass accuracy are very important factors to consider. This makes Fourier 
Transform instruments such as the Orbitrap a natural choice for these methods. The 
impact of mass analysers on vaginal mucosal metabolite profiles captured using 
DESI-MS is presented in Figure 2. Comparatively, the Orbitrap instrument provides 
the best-resolved and most informative mass spectra with the highest spectral 
richness, mass resolution and mass accuracy. TOF-MS results in a similar number 
of detected spectral features as the Orbitrap, however the quality of mass accuracy 
is poorer and harder to stabilise over longer measurement times. The mass 
spectrum acquired with ion-trap provides comparatively lower mass accuracy (>20 
ppm), weaker sensitivity, a smaller number of detected spectral features with 
reduced signal intensities and elevated baseline with lower signal/noise ratio. 
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Nevertheless, the reduced cost of ion trap instruments and their ability to consistently 
detect common, abundant spectral features including lipid molecules makes them 
valuable platforms for point of care diagnostics and biomarker measurements in 
clinical environments. 
 
Figure 2. Comparison of MS spectra of matched cervicovaginal fluid samples 
obtained using a) Orbitrap MS (LTQ-Orbitrap Discovery, Thermo Scientific), b) TOF-
MS (Xevo G2-S, Waters Coorporation) and c) Ion trap MS (LTQ-Orbitrap Discovery, 
Thermo Scientific) mass analysers combined with DESI as a metabolite ionisation 
source in the mass range from m/z 150-900 and m/z 600-900. 
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5. Conclusions 
Detailed examination of host:microbiota interactions at the vaginal mucosal interface 
can be achieved throughout the application of multi-omic approaches including 
molecular, immunological and metabolomic profiling techniques and their integration 
via data fusion strategies. These profiling techniques are in a continual flux of 
development and evolution thus optimisation of the methodological and analytical 
workflow is critical for limiting the introduction of technical and experimental biases 
that can hinder interpretation and reproducibility of data across different studies. 
Despite these challenges, clear relationships exist between vaginal microbiota 
composition and disease-specific host responses that can be examined using 
immunological and metabolic profiling approaches. While validation and confirmation 
of purported mucosal biomarkers is still required, there exists strong potential for the 
development of rapid diagnostic and prognostic applications in women’s health and 
the identification of novel targets for future therapeutic interventions. 
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